Canadian guidelines for the management of plaque psoriasis: Overview

Journal of Cutaneous Medicine and Surgery

Volumn 15, Issue 4, 2011, Pages 210-219

  Papp, Kim ^{a,b,c,d,e,f,g,h,i}   Gulliver, Wayne ^{a,b,c,d,e,f,g,h,i}   Lynde, Charles ^{a,b,c,d,e,f,g,h,i}   Poulin, Yves ^{a,b,c,d,e,f,g,h,i}   Ashkenas, John ^{a,b,c,d,e,f,g,h,i}  

^a K Papp Clinical Research   (Canada)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c Newlab Clinical Research Inc   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e Lynderm Research Inc Canada   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g Meandacute tropolitain   (Canada)

^h UNIVERSITÉ LAVAL   (Canada)

ⁱ SCRIPT   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN;

CANADA; DISEASE SEVERITY; HUMAN; INFORMATION PROCESSING; ONLINE SYSTEM; PATIENT CARE; PHOTOTHERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; ULTRAVIOLET B RADIATION;

CANADA; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PSORIASIS;

EID: 79960719497     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2011.10066     Document Type: Review

References (68)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96, doi:10.1016/S0733- 8635(05)70376-4.
2. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001;137:280-4. (Pubitemid 32240779)
3. Wahl AK, Gjengedal E, Hanestad BR. The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res 2002;12:250-61, doi:10.1177/104973202129119874.
4. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989;20:53-63, doi:10.1016/S0190-9622(89)70007-4.
5. Vardy D, Besser A, Amir M, et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002;147:736-42, doi:10.1046/j.1365-2133.2002.04899.x.
6. Schmid-Ott G, Kuensebeck HW, Jaeger B, et al. Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Derm Venereol 1999;79:443-7, doi:10.1080/000155599750009870.
7. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007;156:1245-50, doi:10.1111/j.1365-2133.2007.07881.x.
8. Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006;17:24-8, doi:10.1080/09546630500482886.
9. Heydendael VM, de Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004;9:131-5, doi:10.1111/j.1087-0024.2004.09115.x.
10. Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004;151:1227-33, doi:10.1111/j.1365-2133.2004.06221.x.
11. Jobling RG. Psoriasis - a preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol 1976;1:233-6, doi:10.1111/j.1365-2230. 1976.tb01424.x.
12. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41, doi:10.1001/jama.296.14.1735.
13. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9, doi:10.1001/archderm.143.12.1493.
14. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. June 2009. Available at: http://www.dermatology. ca/guidelines/cdnpsoriasisguidelines.pdf or http://www.dermatology.ca/ guidelines/LignesdirectricespsoriasisCAN.pdf (accessed on April 2011).
15. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Available at: www.agreecollaboration.org (accessed November 2006).
16. Canadian Medical Association. Handbook on clinical practice guidelines 2007. Available at: http://www.cma.ca//multimedia/CMA/Content-Images/ CMAInfobase/EN/handbook.pdf (accessed June 2007).
17. Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developers' handbook. Available at: www.sign.ac.uk (accessed November 2006).
18. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537-41, doi:10.1001/archderm.141.12.1537.
19. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol 2003;49:651-4, doi:10.1067/S0190-9622(03)00912-5.
20. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004;151:895-7, doi:10.1111/j.1365-2133.2004.06174.x.
21. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol 2007;143:912-5, doi:10.1001/archderm.143.7.912.
22. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19 Suppl 3:2-6, doi:10.1111/j.1468-3083.2005.01329.x.
23. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-3. (Pubitemid 29480408)
24. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64, doi:10.1046/j.1365-2133.2000.04713.x.
25. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-7, doi:10.1136/bmj.320.7240.963.
26. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54, doi:10.1067/mjd.2003. 130.
27. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802, doi:10.1067/mjd.2000. 103983.
28. Lynde CW, Poulin Y, Guenther L, Jackson C. The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009;13:235-52.
29. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg 2009;13:283-93.
30. Wasel N, Poulin Y, Andrew R, et al. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009;13:294-302.
31. Papp K, Carey W. Psoriasis care: new and emerging pharmacologic trends. J Cutan Med Surg 2010;14:119-29.
32. Statistics Canada. Age (123) and sex (3) for the population of Canada, 2006 census. Available at: http://www12.statcan.ca/english/census06/data/topics/ RetrieveProductTable.cfm?Temporal=2006&APATH=3&PID=88989&THEME= 66&PTYPE=88971&VID=0&GK=NA&GC=99&FL=0&RL=0&FREE= 0&METH=0&S=1 (accessed January 2008).
33. Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970-5, doi:10.1111/j.1365-4632.2006.02939.x.
34. Van De Kerkhof PCM. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatolog Ther 2006;19:252-63, doi:10.1111/j.1529-8019.2006.00082.x.
35. Olsen EA, Weed WW, Meyer CJ, Cobo LM. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989;21:681-6, doi:10.1016/S0190-9622(89)70236-X.
36. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999;141:283-91, doi:10.1046/j.1365-2133.1999.02977.x.
37. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-51, doi:10.1067/mjd.2001. 112400.
38. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132:623-9, doi:10.1001/archderm.132.6.623.
39. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol 2001;2:41-7, doi:10.2165/00128071-200102010-00007.
40. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980;102:407-12, doi:10.1111/j.1365-2133.1980.tb06553.x.
41. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996;10:369-75. (Pubitemid 26364819)
42. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154:1169-74, doi:10.1111/j.1365- 2133.2006.07289.x.
43. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65, doi:10.1056/NEJMoa021359.
44. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204-10, doi:10.1111/j.1365-2133.1994.tb02901.x.
45. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US post-marketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94, doi:10.1136/ard.2005.043166.
46. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15, doi:10.1016/j.jaad.2007.09.010.
47. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66. (Pubitemid 351239154)
48. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9, doi:10.1002/1529-0131(200112)44:12〈2862::AID- ART474〉3.0.CO;2-W.
49. Fulchiero GJ, Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56(5 Suppl):S65-7, doi:10.1016/j.jaad.2006.12.024.
50. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006;54(3 Suppl 2):S101-11, doi:10.1016/j.jaad.2005.11.1088.
51. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22, doi:10.1056/ NEJMoa030409.
52. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12, doi:10.1111/j.1365-2133.2005. 06688.x.
53. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56(1):31.el-15, doi:10.1016/j.jaad.2006.07.017.
54. Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study Br J Dermatol 2006;155:160-9, doi:10.1111/j.1365-2133.2006.07316.x.
55. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74, doi:10.1016/S0140-6736(05)67566-6.
56. Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 2006;5:251-4.
57. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912-21, doi:10.1016/j.clinthera.2005.12.007.
58. Legat FJ, Hofer A, Wackernagel A, et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007;143:1016-22, doi:10.1001/archderm.143.8.1016.
59. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624-8.
60. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27, doi:10.1001/archderm.139.6.719.
61. Nijsten TEC, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003;121:252-8, doi:10.1046/j.1523-1747.2003.12350.x.
62. Tzaneva S, Honigsmann H, Tanew A, Seeber A. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002;147:748-53, doi:10.1046/j.1365-2133.2002.04896.x.
63. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70, doi:10.1111/j.1365-2133.1989.tb01354.x.
64. Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682-4, doi:10.1016/0190-9622(91)70253-X.
65. Schiener R, Brockow T, Franke A, et al. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol 2007;143:586-96, doi:10.1001/archderm.143.5.586.
66. Yones SS, Palmer RA, Garibaldinos TT, Hawk JLM. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006;142:836-42, doi:10.1001/archderm.142.7.836.
67. Markham T, Rogers S, Collins P. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen - UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139:325-8, doi:10.1001/archderm.139.3.325.
68. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32, doi:10.1016/S0190-9622(99)70008-3.